158 related articles for article (PubMed ID: 30145016)
21. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy.
Turpin BK; Morris VR; Lemen L; Weiss BD; Gelfand MJ
Health Phys; 2013 Feb; 104(2 Suppl 1):S43-6. PubMed ID: 23287519
[TBL] [Abstract][Full Text] [Related]
22. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Al-Haj AN; Lagarde CS; Lobriguito AM
Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
[TBL] [Abstract][Full Text] [Related]
23. Correction factors for more accurate estimates of exposure rates near radioactive patients: experimental, point, and line source models.
Willegaignon J; Guimarães MI; Stabin MG; Sapienza MT; Malvestiti LF; Marone MM; Sordi GM
Health Phys; 2007 Dec; 93(6):678-88. PubMed ID: 17993848
[TBL] [Abstract][Full Text] [Related]
24. Are restrictions to behaviour of patients required following fluorine-18 fluorodeoxyglucose positron emission tomographic studies?
Cronin B; Marsden PK; O'Doherty MJ
Eur J Nucl Med; 1999 Feb; 26(2):121-8. PubMed ID: 9933345
[TBL] [Abstract][Full Text] [Related]
25. Personal dosimetry of the staff during treatment of neuroendocrine tumours with a high dose of Indium-111 Octreotide.
Stokkel MP; Boot IN; Smit JW
Q J Nucl Med; 2002 Dec; 46(4):331-5. PubMed ID: 12411874
[TBL] [Abstract][Full Text] [Related]
26. [A study on the isolation period of patients with metastatic thyroid cancer treated by 131I according to a new guideline].
Tsuchimochi S; Nakajo M; Umanodan T; Fukushima N; Shigaki S; Kiku T
Kaku Igaku; 2001 Nov; 38(6):747-54. PubMed ID: 11806086
[TBL] [Abstract][Full Text] [Related]
27. [Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures].
Sudbrock F; Boldt F; Kobe C; Hammes J; Eschner W; Schicha H
Nuklearmedizin; 2009; 48(1):17-25. PubMed ID: 19212607
[TBL] [Abstract][Full Text] [Related]
28. Radioactive contamination of contact lenses during radioiodine therapy.
Zettinig G; Karanikas G; Hanselmayer G; Havlik E; Dudczak R
Nucl Med Commun; 2000 Oct; 21(10):955-7. PubMed ID: 11130337
[TBL] [Abstract][Full Text] [Related]
29. Radiation dose to PET technologists and strategies to lower occupational exposure.
Roberts FO; Gunawardana DH; Pathmaraj K; Wallace A; U PL; Mi T; Berlangieri SU; O'Keefe GJ; Rowe CC; Scott AM
J Nucl Med Technol; 2005 Mar; 33(1):44-7. PubMed ID: 15731021
[TBL] [Abstract][Full Text] [Related]
30. Assessment of exposure of workers to ionizing radiation from radioiodine and technetium in nuclear medicine departmental facilities.
Krajewska G; Pachocki KA
Med Pr; 2013; 64(5):625-30. PubMed ID: 24502125
[TBL] [Abstract][Full Text] [Related]
31. THE COMPARISON OF THE EXTERNAL DOSE RATE MEASUREMENT OF CHILDREN AND ADOLESCENT PATIENTS WITH ADULT PATIENTS TREATED WITH RADIOIODINE THERAPY.
Edis N; Tamam MO
Radiat Prot Dosimetry; 2019 Aug; 184(2):168-173. PubMed ID: 30452694
[TBL] [Abstract][Full Text] [Related]
32. Radiation exposure to comforters and carers during paediatric molecular radiotherapy.
Gains JE; Walker C; Sullivan TM; Waddington WA; Fersht NL; Sullivan KP; Armstrong E; D'Souza DP; Aldridge MD; Bomanji JB; Gaze MN
Pediatr Blood Cancer; 2015 Feb; 62(2):235-239. PubMed ID: 25284346
[TBL] [Abstract][Full Text] [Related]
33. Radiation exposure received by the medical radiation workers in Lithuania at the Institute of Oncology, Vilnius University, 2004-2011.
Samerdokiene V; Atkocius V; Ofomala R
Radiat Prot Dosimetry; 2013 Nov; 157(1):152-7. PubMed ID: 23633650
[TBL] [Abstract][Full Text] [Related]
34. A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment.
Azizmohammadi Z; Tabei F; Shafiei B; Babaei AA; Jukandan SM; Naghshine R; Javadi H; Nabipour I; Assadi M; Asli IN
Hell J Nucl Med; 2013; 16(2):103-6. PubMed ID: 23687641
[TBL] [Abstract][Full Text] [Related]
35. Radiation Exposure to the Nuclear Medicine Personnel During Preparation and Handling of
Thakral P; Sen I; Simecek J; Marx S; Kumari J; Kumar S; Tandon P; Dureja S; Pant V
J Nucl Med Technol; 2020 Mar; 48(1):68-72. PubMed ID: 31604889
[TBL] [Abstract][Full Text] [Related]
36. The effects of a custom-made lead collar on dose rates of patients treated with 131I.
Stapel AG; van der Zant FM; Gommans GM; Boer RO; Reigman HI
Health Phys; 2009 May; 96(5 Suppl 2):S64-8. PubMed ID: 19359844
[TBL] [Abstract][Full Text] [Related]
37. Exposure of medical personnel to radiation during radionuclide therapy practices.
Lancelot S; Guillet B; Sigrist S; Bourrelly M; Waultier S; Mundler O; Pisano P
Nucl Med Commun; 2008 Apr; 29(4):405-10. PubMed ID: 18317307
[TBL] [Abstract][Full Text] [Related]
38. Liquid discharges from patients undergoing 131I treatments.
Barquero R; Basurto F; Nuñez C; Esteban R
J Environ Radioact; 2008 Oct; 99(10):1530-4. PubMed ID: 18243440
[TBL] [Abstract][Full Text] [Related]
39. A comprehensive dose reconstruction methodology for former rocketdyne/atomics international radiation workers.
Boice JD; Leggett RW; Ellis ED; Wallace PW; Mumma M; Cohen SS; Brill AB; Chadda B; Boecker BB; Yoder RC; Eckerman KF
Health Phys; 2006 May; 90(5):409-30. PubMed ID: 16607174
[TBL] [Abstract][Full Text] [Related]
40. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
